Palivizumab Utilization and Compliance: Trends in Respiratory Syncytial Virus Prophylaxis in Florida
To access this article, please choose from the options below
Supported in part by a grant from the Florida Agency of Healthcare Administration, AHCA. The authors declare no conflicts of interest.
PII: S0022-3476(09)01245-1
doi:10.1016/j.jpeds.2009.12.016
© 2010 Mosby, Inc. All rights reserved.
